<DOC>
	<DOC>NCT02631512</DOC>
	<brief_summary>The aim of the current study is to support the performance and safety of WoulganÂ® in the treatment of diabetic foot ulcer in comparison with the commercially available hydrogel Intrasite. Healing and untoward medical events to be evaluated.</brief_summary>
	<brief_title>Evaluation of Woulgan in Diabetic Foot Ulcer</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Type I or II diabetes mellitus. Target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old. Anklebrachial pressure index above 0.7. Ulcers due to nondiabetic etiology. Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status. Ulcers older than 1 year. Any of gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>